Evaluating the Evidence for Teratogenicity of Psychotropic Medications

Jeffrey Newport, M.D.

Director of Women's Reproductive Mental Health
UT Health Austin

Learning Objectives

Review evidence-based data regarding potential teratogenicity of psychotropic medications
Discuss best practices regarding use of psychotropic medications during and after pregnancy

Activity Description

This program consists of 1 video and downloadable resources in PDF format. To begin, take the ungraded pre-test for the module below. Review the video and handout(s), then complete the post-test ( > 70% within 5 attempts) and evaluation. CPE credit will automatically upload to CPE Monitor (allow 7 days).

Continuing Education Credit

The University of Texas at Austin College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This online activity is approved for 0.10 CEUs (1.00 contact hour) of continuing education credit. In order to receive 1.00 contact hour of CE credit, the participant must complete the online pre-test (ungraded), watch the included video in its entirety, pass the online post-test ( > 70% within 5 attempts), and complete the online evaluation. Upon successful completion of the course evaluation, continuing pharmacy education credits will automatically be uploaded to CPE Monitor (allow 7 days).

Please make sure NABP profile ID and date of birth (month/year) are entered correctly under learner's profile in this system.

Fee

$12.00

CE Hours

1.00

CE Units

0.100

Activity Type

Knowledge

Evaluating the Evidence for Teratogenicity of Psychotropic Medications

About the Faculty

Jeffrey Newport, M.D.

Director of Women's Reproductive Mental Health
UT Health Austin

Jeffrey Newport is Professor of Psychiatry and Women’s Health at the University of Texas at Austin Dell Medical School where he serves as Associate Chair for Research for the Department of Psychiatry & Behavioral Sciences and Director of Texas Women’s Reproductive Mental Health.. Dr. Newport completed a graduate theological degree before receiving his medical degree from the University of South Carolina. He subsequently completed psychiatric residency and a master’s degree in clinical research at Emory University. His awards include the NARSAD Independent and Young Investigator Awards, Young Faculty Award from the American Psychiatric Institute for Research and Education, the Society of Biological Psychiatry’s Lilly Fellowship, the American College of Psychiatrists’ Laughlin Fellowship, and the Distinguished Physician Alumnus Award from the University of South Carolina. He has published in leading journals across numerous specialties including JAMA, American Journal of Psychiatry, American Journal of Obstetrics & Gynecology, Neurology, and Pediatrics. Dr. Newport’s research focuses on women’s mental health with an emphasis on the psychobiology of perinatal psychiatric disorders, psychotropic pharmacokinetics during pregnancy and lactation, and the persistent biobehavioral impact of childhood trauma and other early life adverse experiences.

Disclosure: Dr. Newport has the following relevant financial relationships, potential or perceived, with commercial or conflicts of interest to disclose:

Grant/Research Support: Eli Lilly, Glaxo Smith Kline, Janssen, Sage Therapeutics, Takeda Pharmaceuticals, Wyeth

Honorarium: Astra-Zeneca, Glaxo Smith Kline, Janssen, Sage Therapeutics, Takeda Pharmaceuticals, Wyeth

Review of Conflicts Policy: The UT Austin College of Pharmacy has a very strict policy to ensure against commercial conflicts of interest in CE programming. For this conference, the planning committee picks two committee members who have appropriate backgrounds to review content, and report any potential conflict of interest to the CPE Director. If conflict issues are discovered, they are addressed with speakers to make appropriate changes. Evaluations are collected from all participants with specific questions around the listed conflicts of commercial interest.

Activity Number

0067-0000-21-198-H04-P

Release Date: Oct 21, 2021

Credit Expiration Date: Oct 20, 2024

CE Hours

1.00